Beyond the Headline: Why Women Deserve the Whole Picture on Hormone Therapy

For most of my career, I have watched women endure years of hot flashes, sleepless nights and silent bone loss because of one study.

In 2002, the Women’s Health Initiative reported that hormone therapy raised the risk of breast cancer, heart disease and stroke. Almost overnight, prescriptions collapsed. Women who had done well on hormones for years were told to stop. A generation of doctors learned to treat these medicines as dangerous.

What got lost was who that study looked at: women averaging 63, roughly a decade past menopause, taking one type of pill. The study answered a narrow question well. We treated it as the answer to every question.

Last November, the FDA removed most of the black box warning that study inspired. I welcome the change. But I worry we haven’t learned the real lesson of how we got here. The problem wasn’t the science. It was how we used it.

Before 2002, large observational studies and decades of clinical experience suggested hormones protected women’s hearts and bones. The randomized trial seemed to say otherwise, and the field set everything else aside. Years later, researchers looked again by age and timing, and the pieces fit. Women who started hormones near menopause fared very differently from the older women who dominated the trial. Neither the observations nor the trial told the whole story alone. The truth was in reading them together.

That is what evidence-based medicine was supposed to be. The evidence isn’t only the findings of studies but also using observation and critical reasoning of those providers and scientists to help see how then studies fit into real world situations.

This matters most when we talk about prevention. The evidence that hormone therapy prevents bone loss and fractures is strong. The FDA now notes that women who start within 10 years of menopause show lower overall death rates in randomized studies. Whether hormones protect the heart or the brain is still debated, and the U.S. Preventive Services Task Force advises against taking them for prevention alone. I respect that caution. But “not yet proven in a trial” is not the same as “no benefit.” A woman deserves the whole picture, not the verdict of one study.

The cost of getting this wrong is real. In 2020, about 41 million American women were between 45 and 64, yet only about 2 million filled a hormone prescription. Some chose not to, and that is their right. I suspect many more were never offered the conversation.

I am not arguing that every woman should take hormones. I am arguing that no woman’s care should be decided by a headline or a single study read in isolation. Good medicine weighs all the evidence, listens to the patient in front of us and trusts the trained judgment of the people caring for her. We practiced that way once. We can again.